You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Checkpoint Inhibitor

Showing 1 - 25 of 8,446
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Immune Checkpoint Inhibitor-related Cardiotoxicity

Not yet recruiting
  • Immune Checkpoint Inhibitors, Cardiotoxicity
  • Cardiac magnetic resonance
  • (no location specified)
Nov 10, 2023

Gastrointestinal Tumor Trial in Hangzhou (Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T,

Completed
  • Gastrointestinal Tumor
  • Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
  • tislelizumab (BeiGene, China) combined with PD-1 inhibitor
  • Hangzhou, China
    Zhejiang Hospital
Sep 1, 2023

Severe Checkpoint Inhibitor Pneumonitis Trial in Beijing (Corticosteroids, Corticosteroids and Ruxolitinib)

Recruiting
  • Severe Checkpoint Inhibitor Pneumonitis
  • Beijing, Beijing, China
    Department of Respiratory Medicine, Peking Union Medical College
Jun 12, 2023

Inflammatory Arthritis, Immune-related Adverse Event Trial (Adalimumab, Prednisone)

Not yet recruiting
  • Inflammatory Arthritis
  • Immune-related Adverse Event
  • (no location specified)
Sep 13, 2023

Immune Checkpoint Inhibitor Monotherapy or Combined With

Not yet recruiting
  • Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeting Drugs / Locoregional Therapy for Hepatocellular Carcinoma
  • Immune checkpoint inhibitor
  • Guangzhou, Guangdong, China
    Department of Minimally Invasive and Interventional Radiology, L
Jan 30, 2023

EXploring Immune-related Adverse Events of Immune checkpoinT

Active, not recruiting
  • Cancer
  • +2 more
  • Immune checkpoint inhibitor
  • Paris, France
  • +1 more
Jul 5, 2023

Liver Metastasis Colon Cancer Trial (IRE plus checkpoint inhibitor, IRE plus Checkpoint Inhibitor plus CpG-ODN)

Not yet recruiting
  • Liver Metastasis Colon Cancer
  • IRE plus checkpoint inhibitor
  • IRE plus Checkpoint Inhibitor plus CpG-ODN
  • (no location specified)
Sep 13, 2023

Stage IV NSCLC Trial in Houston (Poly ICLC, IVIG)

Not yet recruiting
  • Stage IV NSCLC
  • Houston, Texas
    Michael E. DeBakey VA Medical Center, Houston, TX
Sep 28, 2023

Malignant Ascites Trial in Taichung (Nivolumab, Pembrolizumab)

Enrolling by invitation
  • Malignant Ascites
  • Taichung, Please Select, Taiwan
    China Medical University Hospital
Feb 16, 2023

Development ofEORTC Immune Checkpoint Inhibitor-specific Quality

Recruiting
  • Cancer
  • +2 more
    • Paris, France
      Institut Curie
    Nov 2, 2022

    Advanced Solid Tumor Trial (INCB099280)

    Not yet recruiting
    • Advanced Solid Tumor
    • (no location specified)
    May 19, 2023

    Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy Trial (radiation, drug, biological)

    Not yet recruiting
    • Nasopharyngeal Carcinoma
    • +3 more
    • Intensity Modulated Radiation Therapy
    • +3 more
    • (no location specified)
    Jul 11, 2023

    Lung Squamous Cell Carcinoma Trial in Yancheng (To explore the efficacy and safety of immune checkpoint inhibitor combined with

    Recruiting
    • Lung Squamous Cell Carcinoma
    • To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
    • Yancheng, Jiangsu, China
      Yancheng Clinical College of Xuzhou Medical University
    Mar 21, 2023

    Determine Pro-Inflammatory Cytokine Kinetics During Immune

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • Melanoma
      • Indianapolis, Indiana
        Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
      Jan 30, 2023

      Advanced Biliary Tract Cancer Trial in Shanghai (Sintilimab, Lenvatinib, Cryoablation)

      Recruiting
      • Advanced Biliary Tract Cancer
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Mar 22, 2023

      Melanoma Trial in Toulouse (Nivolumab+Ipilimumab in combination with Anti TNF-a Certolizumab, Nivolumab+Ipilimumab in

      Active, not recruiting
      • Melanoma
      • Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
      • Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
      • Toulouse, France
        Institut Claudius Regaud IUCT-ONCOPOLE
      Nov 18, 2022

      Healthcare Resource Utilization and Costs of Immune Checkpoint

      Completed
      • Melanoma
        • East Hanover, New Jersey
          Novartis
        May 12, 2023

        Colitis Trial in Aalborg, Odense, London (Infliximab, Methylprednisolone, Prednisolone)

        Not yet recruiting
        • Colitis
        • Aalborg, Denmark
        • +2 more
        Jul 7, 2023

        Pre-transplant ICI Exposure and Post-transplant Graft Rejection

        Recruiting
        • Graft Rejection
        • +3 more
        • Immune checkpoint inhibitor
        • Guangzhou, Guangdong, China
          Organ Transplantation Center, Sun Yat-sen Memorial Hospital, Sun
        Jun 21, 2023

        Lung Cancer, Immune Checkpoint Inhibitor, Radiotherapy Trial in Chongqing (Super-hyperfractionation Pulse Radiotherapy)

        Recruiting
        • Lung Cancer
        • +2 more
        • Super-hyperfractionation Pulse Radiotherapy
        • Chongqing, Chongqing, China
        • +1 more
        Feb 22, 2023

        Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

        Not yet recruiting
        • Metastatic Pancreatic Cancer
        • Durvalumab
        • Rintatolimod
        • Rotterdam, Zuid-Holland, Netherlands
          Erasmus MC
        Jun 23, 2023

        Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemo Effect Trial in Guangzhou (PD-1 Immune Checkpoint

        Active, not recruiting
        • Recurrent Nasopharyngeal Carcinoma
        • +2 more
        • PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab
        • Guangzhou, Guangdong, China
          Yanqun Xiang
        Sep 5, 2022

        Advanced Malignant Solid Tumor Trial in Huntersville (BNT314, Pembrolizumab)

        Not yet recruiting
        • Advanced Malignant Solid Tumor
        • BNT314
        • Pembrolizumab
        • Huntersville, North Carolina
          Carolina BioOncology Institute, LLC
        Nov 21, 2023

        Immune Checkpoint Inhibitors(ICPis)-Induced Endocrine

        Completed
        • Immune Checkpoint Inhibitor
        • Endocrine Toxicity
          • Nanjing, Jiangsu, China
            First Affiliated Hospital, Nanjing Medical University
          Jan 6, 2023

          Troponin to Detect Major Cardiovasculaire Advserse Events on

          Recruiting
          • Cancer
          • +2 more
          • No intervention
          • Paris, France
            Institut Mutualiste Montsouris
          Aug 22, 2023